2026-04-03
Gut microbiota: metabolites at the heart of cardiovascular risk
Cardiology and Vascular Medicine Gastroenterology and Hepatology
By Elodie Vaz | Published on April 3, 2026 | 4 min read
Coronary heart disease remains the leading cause of mortality worldwide. Its development relies on a complex interplay of genetic, metabolic, and environmental factors. Among these, the role of the gut microbiota has attracted growing interest. Acting as a true metabolic organ, it produces a wide range of molecules capable of entering the bloodstream and influencing host physiology—sometimes in harmful ways.
A study published on March 17 in PLOS Medicine aimed to better understand the links between microbial metabolites and the risk of coronary heart disease. The researchers sought to identify, using large-scale human data, metabolic signatures associated with the onset of this cardiovascular condition.
To address this question, the team led by Professor Danxia Yu conducted a multi-phase analysis using blood samples from several thousand adults across diverse populations (African American, Caucasian, and Asian), in the United States and Shanghai.
Initially, nearly 2,000 participants were analyzed to identify gut microbiota-derived metabolites associated with coronary disease risk. These associations were then validated in independent cohorts, with adjustments for numerous conventional risk factors such as age, diet, and family history.
The final analysis identified nine specific metabolites whose blood concentrations were associated with coronary heart disease risk—some linked to increased risk, others suggesting a potentially protective effect.
Notably, these associations persisted after adjustment for confounding variables and remained robust in certain subpopulations. However, variations were observed depending on ethnicity and age, suggesting complex interactions between the microbiota, environmental factors, and individual susceptibility.
These findings reinforce the hypothesis that the gut microbiota plays an active role in cardiovascular pathophysiology through metabolic mechanisms that are still only partially understood.
Beyond statistical associations, this study opens important translational perspectives. The identified metabolites could serve as biomarkers to refine cardiovascular risk stratification, and potentially as targets for new preventive or therapeutic interventions.
The authors emphasize that this is one of the most comprehensive metabolomic studies to date, encompassing discovery, in silico validation, and quantitative validation across ethnically and geographically diverse populations. “Our findings highlight the importance of gut microbial metabolism in the development of cardiovascular diseases and identify promising molecules that could serve as new biomarkers or therapeutic targets for future mechanistic and interventional studies.”
Although further mechanistic investigations are needed, these results confirm the emergence of the gut microbiota as a key player in cardiovascular health. They encourage moving beyond traditional risk factor–centered approaches to integrate host–microbiome interactions.
In the long term, modulation of the gut microbiota—through diet, probiotics, or novel pharmacological approaches—could become part of coronary disease prevention strategies. This perspective opens a promising field of research at the intersection of cardiology, metabolism, and microbiology.
About the Author – Elodie Vaz
Health journalist, CFPJ graduate (2023).
Élodie explores the marks diseases leave on bodies and, more broadly, on human life. A registered nurse since 2010, she spent twelve years at patients’ bedsides before exchanging her stethoscope for a notebook. She now investigates the links between environment and health, convinced that the vitality of life cannot be reduced to that of humans alone.
Coronary heart disease remains the leading cause of mortality worldwide. Its development relies on a complex interplay of genetic, metabolic, and environmental factors. Among these, the role of the gut microbiota has attracted growing interest. Acting as a true metabolic organ, it produces a wide range of molecules capable of entering the bloodstream and influencing host physiology—sometimes in harmful ways.
A study published on March 17 in PLOS Medicine aimed to better understand the links between microbial metabolites and the risk of coronary heart disease. The researchers sought to identify, using large-scale human data, metabolic signatures associated with the onset of this cardiovascular condition.
A multi-cohort, multi-step analysis
To address this question, the team led by Professor Danxia Yu conducted a multi-phase analysis using blood samples from several thousand adults across diverse populations (African American, Caucasian, and Asian), in the United States and Shanghai.
Initially, nearly 2,000 participants were analyzed to identify gut microbiota-derived metabolites associated with coronary disease risk. These associations were then validated in independent cohorts, with adjustments for numerous conventional risk factors such as age, diet, and family history.
Nine metabolites linked to cardiovascular risk
The final analysis identified nine specific metabolites whose blood concentrations were associated with coronary heart disease risk—some linked to increased risk, others suggesting a potentially protective effect.
Notably, these associations persisted after adjustment for confounding variables and remained robust in certain subpopulations. However, variations were observed depending on ethnicity and age, suggesting complex interactions between the microbiota, environmental factors, and individual susceptibility.
These findings reinforce the hypothesis that the gut microbiota plays an active role in cardiovascular pathophysiology through metabolic mechanisms that are still only partially understood.
Emerging biomarkers and therapeutic targets
Beyond statistical associations, this study opens important translational perspectives. The identified metabolites could serve as biomarkers to refine cardiovascular risk stratification, and potentially as targets for new preventive or therapeutic interventions.
The authors emphasize that this is one of the most comprehensive metabolomic studies to date, encompassing discovery, in silico validation, and quantitative validation across ethnically and geographically diverse populations. “Our findings highlight the importance of gut microbial metabolism in the development of cardiovascular diseases and identify promising molecules that could serve as new biomarkers or therapeutic targets for future mechanistic and interventional studies.”
Toward microbiome-integrated cardiovascular medicine
Although further mechanistic investigations are needed, these results confirm the emergence of the gut microbiota as a key player in cardiovascular health. They encourage moving beyond traditional risk factor–centered approaches to integrate host–microbiome interactions.
In the long term, modulation of the gut microbiota—through diet, probiotics, or novel pharmacological approaches—could become part of coronary disease prevention strategies. This perspective opens a promising field of research at the intersection of cardiology, metabolism, and microbiology.
Read next: Myocardial infarction: a single-dose drug to support heart repair
About the Author – Elodie Vaz
Health journalist, CFPJ graduate (2023).
Élodie explores the marks diseases leave on bodies and, more broadly, on human life. A registered nurse since 2010, she spent twelve years at patients’ bedsides before exchanging her stethoscope for a notebook. She now investigates the links between environment and health, convinced that the vitality of life cannot be reduced to that of humans alone.
Last press reviews
Breast cancer: circulating tumor DNA, a key biomarker to anticipate relapse
By Elodie Vaz | Published on April 3, 2026 | 3 min read<br><br><br>B...
Gut microbiota: metabolites at the heart of cardiovascular risk
By Elodie Vaz | Published on April 3, 2026 | 4 min read<br><br><br>C...
Vaccine hesitancy: what if listening made all the difference?
By Ana Espino | Published on April 2, 2026 | 4 min read<br>